Hydrogen Research Study
← Back to Research Library
Preclinical animal evidenceAnimal studyOther or not reported

Hydrogen inhalation during normoxic resuscitation improves neurological outcome in a rat model of cardiac arrest independently of targeted temperature management.

Kei Hayashida, Motoaki Sano, Naomi Kamimura, Takashi Yokota, Masaru Suzuki, Shigeo Ohta, Keiichi Fukuda, Shingo Hori · Circulation · 2014

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Cardiovascular Health
Evidence type Preclinical animal evidence
Publication type Animal study
Hydrogen method Other or not reported

H2HUBB TAKEAWAY

In rats, neuronal degeneration and microglial activation in a vulnerable brain region was suppressed by both TTM alone and H₂ inhalation alone, with the combined therapy of TTM and H₂ inhalation being most effective. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.

What the Findings Mean

H2HUBB reviewed how molecular hydrogen affected the outcomes measured in rats. Neuronal degeneration and microglial activation in a vulnerable brain region was suppressed by both TTM alone and H₂ inhalation alone, with the combined therapy of TTM and H₂ inhalation being most effective.

What the Researchers Studied

The researchers studied rats. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.

What Effects Did Molecular Hydrogen Have?

Source-reported hydrogen concentration: 1.3% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 1.3% source-reported H₂ gas concentration. Neuronal degeneration and microglial activation in a vulnerable brain region was suppressed by both TTM alone and H₂ inhalation alone, with the combined therapy of TTM and H₂ inhalation being most effective. The authors concluded that H₂ inhalation was beneficial when begun after ROSC, even when delivered in the absence of hyperoxia.

Why These Findings Matter

These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.

How Strong Is This Evidence?

This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.

Technical Study Details

H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment. The source-reported hydrogen concentration was 1.3% source-reported H₂ gas concentration.

Limitations and Safety

No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.

Original Study and H2HUBB Research Context

H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.